BC230488 (LIN, WEEI-CHIN)Mar 1, 2024 - Feb 28, 2027 Department of Defense Breast Cancer Research Program Breakthrough Award 2 –Funding Level 2 Synthetic Lethal Combination Targeting TopBP1 and Arachidonic Acid Pathway in Breast Cancer Role: Principal Investigator |
|
1R01CA269971-01A1 (LIN, WEEI-CHIN)Apr 17, 2023 - Mar 31, 2028 NIH/NCI 14-3-3tau drives estrogen receptor loss and breast cancer progression Role: Principal Investigator |
|
R01CA269971 (LIN, WEEI-CHIN)Apr 17, 2023 - Mar 31, 2028 NIH 14-3-3tau drives estrogen receptor loss and breast cancer progression Role: Principal Investigator |
|
LC210369 (LIN, WEEI-CHIN)Aug 1, 2022 - Jul 31, 2024 Department of Defense Lung Cancer Research Program Idea Development Award-Established Investigator New therapeutics targeting MYC and immune escape in lung cancer Role: Principal Investigator |
|
BC210863 (LIN, WEEI-CHIN)May 15, 2022 - May 14, 2025 Department of Defense Breast Cancer Research Program Expansion Award Novel Synthetic Lethal Therapies for Triple-Negative Breast Cancer Role: Principal Investigator |
|
2R01CA203824-06A1 (LIN, WEEI-CHIN)Feb 1, 2022 - Jan 31, 2027 NIH/NCI Novel therapeutics for targeting checkpoint dysfunction in cancer Role: Principal Investigator |
|
Pilot Award (LIN, WEEI-CHIN)Apr 1, 2021 - Mar 31, 2023 Rivkin Center for Ovarian Cancer Pilot Award Novel approaches to target MYC in ovarian cancer Role: Principal Investigator |
|
BC181104 (LIN, WEEI-CHIN)Aug 1, 2019 - Jul 31, 2023 Department of Defense Breast Cancer Research Program Expansion Award Title: Inducing BRCAness to synergize with PARP inhibitors in breast cancer Role: Principal Investigator |
|
BC171396 (LIN, WEEI-CHIN)Sep 30, 2018 - Sep 29, 2022 Department of Defense Breast Cancer Research Program Breakthrough Award 2 –Funding Level 2 Exploiting a new Achilles’ heel of mutant p53 in breast cancer Role: Principal Investigator |
|
R01CA203824 (LIN, WEEI-CHIN)Dec 15, 2016 - Jan 31, 2027 NIH Novel therapeutics for targeting checkpoint dysfunction in cancer Role: Principal Investigator |
|
R21CA198041 (LIN, WEEI-CHIN)Jun 1, 2016 - May 31, 2019 NIH New mechanisms of breast cancer metastasis and loss of estrogen receptor driven by 14-3-3 Role: Principal Investigator |
|
Pilot Award (LIN, WEEI-CHIN)Apr 1, 2016 - Mar 31, 2017 Rivkin Center for Ovarian Cancer Target a new mechanism of checkpoint defect in ovarian cancer Role: Principal Investigator |
|
BC133678 (LIN, WEEI-CHIN)Sep 30, 2014 - Sep 29, 2018 Department of Defense Breast Cancer Research Program Breakthrough Award 2 –Funding Level 2 Targeting a convergent point of multiple oncogenic pathways in breast cancer, a new paradigm for targeted therapy Role: Principal Investigator |
|
OC130395 (LIN, WEEI-CHIN)Sep 15, 2014 - Sep 14, 2017 Department of Defense Ovarian Cancer Research Program Novel approaches to target mutant p53 gain-of-function in ovarian cancer Role: Principal Investigator |
|
T32CA174647 (LIN, WEEI-CHIN)Aug 5, 2014 - Jul 31, 2020 NIH BCM Oncology Scholars Training Program Role: Principal Investigator |
|
R01CA138641 (LIN, WEEI-CHIN)Apr 1, 2010 - Jan 31, 2016 NIH Therapeutic Targeting of Oncogenic Stress in Cancer Treatment Role: Principal Investigator |
|
BC084561 (LIN, WEEI-CHIN)Jun 1, 2009 - Mar 31, 2014 Department of Defense Breast Cancer Research Program Regulation of p21 turnover by 14-3-3tau: a basis for novel therapeutic strategies against breast cancer Role: Principal Investigator |
|
The Leukemia & Lymphoma Society Scholar Award (LIN, WEEI-CHIN)Jul 1, 2006 - Jun 30, 2011 The Leukemia & Lymphoma Society The function and regulation of TopBP1 in growth and DNA damage response Role: Principal Investigator |
|
BC031962 (LIN, WEEI-CHIN)Mar 25, 2004 - Mar 24, 2008 Department of Defense The Role of TopBP1 in Breast Cancer Role: Principal Investigator |
|
R01CA100857 (LIN, WEEI-CHIN)Apr 1, 2003 - Feb 28, 2021 NIH The ATM/E2F1 Pathway in DNA Damage and Growth Control Role: Principal Investigator |
|
General Motors Cancer Research Scholar (LIN, WEEI-CHIN)Jan 7, 2002 - Jan 7, 2005 General Motors Cancer Research Scholars Program Regulation of E2F1 by ATM Role: Principal Investigator |